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ABSTRACT 
THE DEVELOPMENT OF VDR-COACTIVATOR INHIBITORS 
AND THEIR EVALUATION USING BIOCHEMICAL AND 
CELL-BASED ASSAYS 
by 
 
Belaynesh D Feleke 
 
The University of Wisconsin-Milwaukee, 2014 
Under the Supervision of Professor Alexander Arnold, PhD 
 
 
The vitamin D receptor (VDR) belongs to the family of nuclear receptors and plays a 
crucial role in many biological processes such as cell differentiation, cell proliferation 
and calcium homeostasis. VDR is a good pharmaceutical target for many diseases 
including cancer, metabolic disorders, skin diseases and cardiovascular diseases. Upon 
binding with its endogenous ligand calcitriol in the body, VDR undergoes a 
conformational change that disrupts the interaction with corepressor proteins and instead 
enables the interaction with coactivator proteins that mediated transcription. The goal of 
the research is the development of new small molecules that will selectively inhibit the 
interaction between VDR and coregulators by binding to the ligand binding site of VDR.   
Eleven VDR antagonists were synthesized based on GW0742 a potent PPARδ agonist 
that inhibit VDR-mediated transcription at higher concentrations. The compounds were 
evaluated using cell-based and biochemical assays to determine their ability to inhibit the 
interaction between VDR and steroid receptor coactivator-2 (SRC-2) and to determine 
 iii 
 
the ability to activate PPARδ mediated transcription.  BF040813F and BF090813A1 were 
the most active compounds towards VDR without activating PPARδ. The simple 
accessibility of BF040813F, being a precursor compound, makes it an attractive 
candidate for further SAR studies.  
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CHAPTER I 
1. INTRODUCTION    
The vitamin D receptor (VDR) is a transcription factor that belongs to the 
superfamily of 48 nuclear receptors (NRs). As a member of nuclear receptors, it mediates 
the transcription of genes responsible for cell differentiation, cell proliferation and 
calcium homeostasis.[1] 
VDR is also pharmaceutical target for several diseases including, skin diseases, hyper-
proliferative diseases, such as psoriasis, benign prostate hyperplasia, different types of 
cancer, autoimmune diseases, microbial infections, and osteoporosis. 
Nuclear receptors generally share a common structural organization (Figure 1).[2] 
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Figure 1: General structure of nuclear receptor 
The N-terminal domain is highly variable depending on the receptor and contains 
a ligand-independent transactivation domain termed “Activation Function 1” (AF-1). The 
most conserved central region of the nuclear receptors is the DNA-binding domain 
(DBD) or the C domain, which is responsible for direct DNA interaction. Its main 
function is to recognize and bind specific DNA regulatory sites called response elements 
(REs). The flexible hinge, or D region, links the C-domain to the ligand-binding (E/F) 
domain. The ligand binding domain of nuclear receptors comprises the ligand binding 
pocket and also acts as a molecular switch by interpreting the ligand structure into 
conformational changes converting the receptor into an activator or repressor. The LBD 
remains the main feature that triggers biological responses to very diverse lipophilic 
molecules. The F domain is located at the end C-terminus of NRs. Because of its high 
variability in sequence, little is known about its structure and functional role.[3] 
1.1 1, 25-Dihydroxyvitamin D3 
The vitamin D hormone, 1, 25-dihydroxyvitamin D3 [1,25(OH)2D3], binds VDR 
with high affinity (Figure 2).[4] 
 
3 
 
 
 
 
Figure 2. Chemical structure of 1, 25-(OH)2D3. 
Its precursor, Vitamin D (Figure 3), can be obtained through foods we eat or can 
be synthesized from 7-dehydrocholesterol through photolysis occurring in the skin.[5]  
 
Figure 3: Vitamin D formation and metabolism. [6] 
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From there, the vitamin D binding protein shuttles vitamin D  to the liver, where it 
is hydroxylated at carbon 25 by vitamin D 25-hydroxylase, resulting in the formation of 
25-hydroxyvitamin D3.[6] Vitamin D3 then binds to its binding protein and is transported 
to the kidneys. In the kidneys, 25-hydroxyvitamin D3 is then hydroxylated at carbon 1 of 
the A ring, which converts the vitamin D3 to the active form, 1, 25-dihydroxyvitamin 
D3.[7]  Vitamin D3 and its derivatives are metabolized in the presence of 24-hydroxylase 
to 24-hydroxylated products and eventually forming calcitroic acid.[8, 9]   
2.2 VDR-mediated transcription 
 
In the nucleus, VDR binds DNA and forms a heterodimer with the retinoid X 
receptor (RXR) (Figure 4). [10] 
 
 
 
 
 
 
Figure 4: VDR-retinoid x receptor dimer in the absence of ligand. 
 RxRE VDRE 
RXR VDR 
Cell 
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RXR is also a nuclear receptor and binds 9-cis retinoic acid.[11] In the absence of 
the ligand, VDR is associated with corepressors such as the nuclear receptor corepressor 
(N-CoR) and the silencing mediator of retinoic acid and thyroid hormone receptor 
(SMRT).[12] N-CoR and SMRT are corepressor proteins that function to repress the 
transcriptional activity of VDR. Ligand binding, on the other hand, permits VDR-
coactivator interactions, and allows the formation of multi-protein complexes that 
activate VDR-mediated transcription (Figure 5).  
 
Figure 5: Binding of a ligand enables VDR to perform transcription 
In the presence of 1, 25-(OH)2 D3,  the VDR-LBD undergoes a conformational change 
which prevents corepressor binding and permits interactions with coactivator proteins 
such as steroid receptor coactivator 2, resulting in the formation of a multi-protein 
complex that activates VDR-mediated transcription. [13-15] 
 
Coactivator	  Complex 
Transcription Polymerase VDR RXR 
corepressor 
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1.3 VDR Antagonist 
 
VDR, as stated earlier, is a pharmaceutical target for different disorders including, 
cancer, skin disorder and autoimmune diseases. One way to modulate VDR-mediated 
transcription is the development of small molecules that inhibit the interactions between 
VDR and coregulators (corepressor and coactivators). Recently, VDR-coactivator 
inhibitors have been introduced by other groups and us.[16-19]  The inhibition of VDR-
coregulator interactions has shown to selectively modulate the expression of specific 
VDR genes. Most of the VDR antagonists developed are based on the secosteroidal 
scaffold, which is very hydrophobic and metabolically less stable. Our research presented 
herein, focuses on the introduction of non-secosteroidal VDR antagonists. These 
compounds have to be selective towards VDR without binding to other NRs.  
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CHAPTER II 
2. SYNTHESIS OF NEW VDR ANTAGONISTS 
2.1. Introduction 
A HTS campaign in collaboration with NIH investigating 390000 molecules led 
to the identification of GW0742 (Figure 6) as a competitive VDR antagonist.[24] 
 
 
 
 
 
 
 
 
 
 
Figure 6: Structure of compound GW 0742. 
 GW0742 was introduced by GlaxoSmithKline in 2003 as a highly selective 
agonist for PPARδ.[25] Since then, compound GW0742 has been investigated in cell-
based assays and in vivo, in order to understand the role of PPARδ in hypertension, 
diabetes, inflammation, obesity, and cancer[26, 27]. Research by other groups and us has 
shown that GW0742 inhibited the transcription of the VDR target gene, CYP24A1, in the 
presence of 1,25-(OH)2D3.[28] It was determined that at micro molar concentrations 
GW0742 behaved as an antagonist of VDR.[24]   
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2.2. New proposed VDR antagonists  
 
The approach for generating new selective and potent VDR antagonists involved 
the variation of different parts of the GW0742 molecule (Figure 7).  
 
 
Figure 7: Different parts of the GW0742 molecule that were modified 
The variation of the turquoise aryl moiety was carried out in collaboration with the NIH. 
The analysis of the compounds and their corresponding potency towards VDR 
antagonism and selectivity among nuclear receptors identified 2- and 3-methoxy as well 
as 2- and 3-trifluoromethyl substituents as superior among 87 compounds tested. With 
this in mind, we concentrated on the substitution of the thiazole moiety (yellow) with an 
aryl ring system and concentrated on the connectivity between the two moieties as 
depicted in Figure 8.   
F3C
F
S
N
CH3
S
O
OH
O
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Figure 8: New proposed VDR antagonists 
The different connectivity of the proposed VDR antagonists introduces a range of 
different angles. Our hypothesis is that this change will not only influence the affinity of 
these compounds towards VDR but also change the selectivity towards other nuclear 
receptors. Furthermore, we will introduce different substitutents especially 2- and 3-
methoxy as well as 2- and 3-trifluoromethyl substituents to optimize their potency.   
2.3. Synthesis of proposed new VDR antagonists 
2.3.1. Synthesis of 4-substituted VDR antagonists 
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The first step of the synthesis of the 4-substituted VDR antagonists started with the 
reduction of the carboxylic acid 1.1 to make the alcohol 1.2 was realized in the present of 
lithium aluminum hydride at 0°C in THF (Scheme 1). After a reaction time of 6 hours the 
reaction was quenched with 1M HCl and the corresponding product was isolated in a 
yield of 51%.   
 
Figure 9: Synthesis of compound 1.6 
The chloride 1.3. was formed with 1.2 in the presence of thionyl chloride.The 
excess of SOCl2 was evaporated after 3 hours followed by evaporation at high vacuum 
overnight giving 1.3 in 75% yield. The reduction of 1.1 in the presence of LiAlH4 also 
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formed 2-methyl benzyl alcohol, which was separated by a high vacuum step from the 
product by leaving it under high vacuum overnight. The chloride 1.3 is then coupled with 
the phenol in the presence of Cs2CO3 to form the ester 1.4 in 66%. The product is 
purified using column chromatography using a solvent gradient from 32% to 60% ethyl 
acetate in hexanes. Suzuki coupling reaction was then used to form 1.4 with 4-
(Trifluoromethyl) phenyl boronic acid in the presence of Pd(PPh3)2Cl2  to form 1.5 which 
is further hydrolyzed to the carboxylic acid final product 1.6.  
 
2.3.2. Synthesis of 3-substituted VDR antagonists 
The next analogue synthesis of the 3-substituted VDR antagonists started with the 
reduction of the carboxylic acid 2.1 to make the alcohol 2.2 in the present of lithium 
aluminum hydride at 0°C in THF (Scheme 2). After a reaction time of 6 hours the 
reaction was quenched with 1M HCl and the corresponding product was isolated in a 
yield of 51%. The chloride 2.3 was formed with 2.2 in the presence of thionyl chloride. 
The excess of SOCl2 was evaporated after 3 hours followed by evaporation at high 
vacuum overnight giving 2.3 in 75% yield. The chloride 2.3 is then coupled with the 
phenol in the presence of Cs2CO3 to form the ester 2.4 in 66% yield. The product is 
purified using column chromatography using a solvent gradient from 32% to 60% ethyl 
acetate in hexanes. Suzuki coupling reaction was then used to form 2.4 with 2 methyl 
12 
 
 
 
methoxy phenyl boronic acid in the presence of Pd(PPh3)2Cl2  to form 2.5. The ester was 
further hydrolyzed to an acid in the presence of 8M NaOH to give 1.6.  
 
 
 
Figure 10: Synthesis of compound 2.6. 
2.3.3. Synthesis of 5-substituted VDR antagonists 
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The next step of the synthesis of the 5-substituted VDR antagonists started with 
the reduction of the carboxylic acid 3.1 to make the alcohol 3.2 in the present of lithium 
aluminum hydride at 0°C in THF (Scheme 3). After a reaction time of 6 hours the 
reaction was quenched with 1M HCl and the corresponding product was isolated in a 
yield of 51%. The chloride 3.3 was formed with 3.2 in the presence of thionyl chloride. 
The excess of SOCl2 was evaporated after 3 hours followed by evaporation at high 
vacuum overnight giving 3.3 in 75% yield. The chloride 3.3 is then coupled with the 
phenol in the presence of Cs2CO3 to form the ester 3.4 in 66%. The product is purified 
using column chromatography using a solvent gradient from 32% to 60% ethyl acetate in 
hexanes. Suzuki coupling reaction was then used to form 3.4 with 4-(Trifluoromethyl) 
phenyl boronic acid in the presence of Pd(PPh3)2Cl2  to form 3.5 which is further 
hydrolyzed to the carboxylic acid final product 3.6.  
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Figure 11: Synthesis of compound 3.6. 
 2.4. Experimental section 
The carboxylic acid 1.1 (4.0g, 18.6mmol) in anhydrous 
THF (35mL) was added drop wise to LiAlH4 (0.88g, 
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23.19mmol) in anhydrous THF (44mL) at 0°C over 30 minutes. The resulting mixture 
was slowly warmed to room temperature and stirred for 7 hours. The reaction was slowly 
quenched with water (300mL) acidified to PH<2. The mixture was worked up with DCM 
three times and was dried over Na2SO4.    The organic layer was concentrated to give a 
white solid. The crude product 1.2 was left in the high vacuum over night and was used 
in the next step without purification. 1HNMR (300MHz) (CDCl3) δ 7. 29(d, 1H); 7.14 (s, 
1H,); 7.12 (1H, d); 4.51 (s, 2H); 2.25 (s, 3H). 13C NMR δ 19.84, 25.52, 67.91, 130.37, 
135.53, 136.83, 172.16.  
 
 The alcohol 2.2 (2g, 9.95mmol) was 
dissolved in Dichloromethane (4mL). Thionyl 
chloride (1.6mL) was slowly added drop wise to 
the above solution. The resulting mixture was 
stirred at room temperature for 24 hours. The 
organic solvent was removed using a rotary evaporator. The product 2.3 was then left 
under high vacuum overnight. 1HNMR (300MHz) (CDCl3) δ 7. 38(d, 1H,); 7.36 (s, 1H); 
7.21 (d, 1H); 4.57 (s, 2H); 2.45 (s, 3H). From the 13C NMR the peak at δ 138.60, 133.78, 
132.68, 130.47, 128.56, 121.94, 43.19, and 17.8 confirmed the formation of the chloride. 
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The crude benzyl 
chloride 1.3 (1.5g, 6.83mmol) 
and the phenol (1.5g, 
8.33mmol) were dissolved in 
acetone (12mL) and treated with Cs
2
CO
3 
(0.6g). The reaction was stirred at 50°C for 16 
hours. The reaction mixture was worked up with DCM three times and was dried over 
Na
2
SO
4
. The organic layer was concentrated to give a while solid. The crude product 1.4 
was purified by column chromatography with a solvent gradient from 32% to 60% ethyl 
acetate in hexanes. The fractions were concentrated to a white solid. 1HNMR (300MHz) 
(CDCl3) δ 7.39(s,1H,); 7.35 (1H,d, J=12);7.31 (d,1H,J=12); 7.17 (d,1H,J=9); 7.15(d, 1H, 
J=9); 6.94(d,1H, J=9 ); 6.91 (d,1H,J=9);4.96 (s,2H); 3.7 (s, 3H); 2.96-2.91 ( t, 3H,J=6); 
2.66-2.61 (t,2H J=6) ); 2.36, (s, 3H). 13C NMR δ 173.15, 166.43, 148.95, 138.67, 137.11, 
135.30, 130.87, 130.05, 129.08, 121.47, 119.28, 51.69, 35.63, 30.35, 19.75. 
 
Commercially available 4-
(Trifluoromethyl) phenyl boronic acid 
(100mg, mmol) and the ester 1.4 
(51mg mmol) were suspended in 
DMF (4mL) and water (200 µL). 
PdCl2 (pph3)2   (10mg, mmol) was added followed by Cs2CO3 (292mg, mmol). The 
resulting mixture was stirred in the microwave at 160 °C for 10 min. The mixture was 
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acidified to PH<2. The reaction was worked up with DCM three times and dried over 
Na2SO4. The crude product 1.4 was purified by column chromatography with a gradient 
of 30% to 62% ethyl acetate in hexanes. The fractions were concentrated to a white solid. 
1HNMR (300MHz) (CDCl3) δ 7.41-7.28(m, 6H); 7.06 (s,1H); 7.04 (d,1H, J=9); 7.02(d, 
1H, J=9); 6.99(d,1H, J=9 ); 6.94 (d,1H,J=9); 5.04 (s,2H); 3.7 (s, 3H); 2.97-2.92 ( t, 2H, 
J=6 ); 2.72-2.67 (t , 2H J=6) ); 2.44 (s, 3H). 13C NMR δ 178.54, 157.62, 156.49, 138.59, 
136.30, 133.51, 132.56, 131.56, 130.65, 129.26, 128.63, 128.41, 127.27, 120.80, 
114.66,111.15,  68.56, 60.43, 55.51, 35.83, 29.04, 19.10. 
 
The ester 1.5 is hydrolyzed to the carboxylic acid form. 1.5 (20mg) of the ester was 
dissolved in THF (1.5mL). 8M NaOH 
(0.15mL) was added and the resulting 
mixture was stirred over night at room 
temperature.  The mixture was acidified to PH<2. The reaction was worked up with DCM 
three times and dried over Na2SO4. The organic layer was concentrated to a white solid.   
1HNMR (300MHz) (CDCl3) δ 7.41-7.28 (m, 6H); 7.19-7.16 (m,2H); 7.04 (d,1H,J=9); 
7.02(d, 1H, J=9); 6.99(d,1H, J=9 ); 6.94 (d,1H,J=9);5.07 (s,2H); 3.83 (s,3H) ; 2.97-2.92 ( 
t, 2H,J=6 );2.72-2.67 (t ,2H J=6) ); 2.44 (s, 3H). 13C NMR δ 176.22, 157.62, 156.49, 
136.31, 133.51, 132.49, 131.56, 130.42, 130.85, 129.28, 128, 128.63, 127.26, 120.80, 
114.86,111.15,  68.56, 55.53, 35.75, 29.52, 19.24.    
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Compound 1.7 was synthesized using the same procedure as compound 1.6. A new 
boronic acid was however used. 
The hydroxyl group was found to 
be active on a HTS with the NIH. 
Therefore (4-(hydroxymethyl) 
phenyl) boronic acid was also used to couple with the 1.5 ester. Proton and Carbon NMR 
confirmed the formation of this acid. 1HNMR (300MHz) (CDCl3) δ 7.50 (s, 1H); 7.49 -
7.35 (m, 6H); 7.21 (d,1H,J=9); 7.18(d, 1H, J=9); 6.98(d,1H, J=9 ); 6.95 (d,1H, J=9); 5.12 
(s, 2H); 4.70 (s, 3H) ; 2.87-2.82 ( t, 2H, J=6 ); 2.60-2.55 (t, 2H,J=6) ); 2.44 (s, 3H). 13C 
NMR δ 173.42, 157.36, 137 .38, 135.05, 133.08, 129.38, 129.27, 127.38, 225.73, 125.67, 
124.92, 114.82, 68.27, 51.62, 35.98, 30.13, 19.08. 
 
  
Compound 1.8 was also synthesized 
the same way as compound 1.6 using a 
different boronic acid. The trifluoro group 
on the ring which was also on the 
GWO742 molecule and has shown 
activity and hence was worth investigating. Therefore, 4-(Trifluoromethyl) phenyl) 
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boronic acid was also coupled with the ester compound to give 1.8. 1HNMR (300MHz) 
(CDCl3) δ 7.7 (m, 4H); 7.55-7.48 (m, 3H); 7.19 (d,1H, J=9); 7.16 (d, 1H, J=9); 6.96 
(d,1H, J=9 ); 6.95 (d,1H, J=9); 5.09 (s, 2H); 3.7 (s,3H); 2.97-2.92 ( t, 2H,J=6 ); 2.67-2.64 
(t, 2H J=6) ); 2.48 (s, 3H). 13C NMR δ 173.41, 157.35, 137.37, 135.06, 133.07, 129.33, 
129.37, 129.27, 127.38, 225.71, 125.67, 124.92, 114.81, 68.20, 51.62, 35.97, 30.12, 
19.08. 
 
Reaction scheme 2 was 
performed the exact same way as 
reaction scheme 1.  The 
corresponding NMR readings are 
as follows. 2.2: 1HNMR 
(300MHz) (CDCl3) δ 7. 52-
7.00(m, 3H,); 4.6 (s, 2H); 2.35 (s, 
3H). From the 13C NMR the peak 
at δ 61 confirmed the reduction to the alcohol. The crude NMR for 2.3 is as follows, 
1HNMR (300MHz) (CDCl3) δ 7. 59-7.04 (m, 3H,); 4.65 (s, 2H); 2.54 (s, 3H). From the 
13C NMR δ 139.80 135.01, 130.98, 129.91, 127.81, 125.65, 43.76, 19.93. Peak 43.7 
confirmed the formation of the chloride. Pure NMR for 2.4 was 1HNMR (300MHz) 
(CDCl3) δ7.41- 6.94(m, 7H); 5.04 (s, 2H); 3.7 (s, 3H); 2.98-2.93 (t, 2H, J=6); 2.69-2.64 
(t, 2H, J=6); 2.48 (s, 3H). 13C NMR δ 173.15, 157.43, 148.95, 138.67, 137.11, 135.30, 
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130.87, 129.05, 129.08, 118.60, 119.28, 68, 51.63, 35.97, 30.15, 18.73. NMR for 2.5: 
1HNMR (300MHz) (CDCl3) δ7.42-6.97(m, 11H); 5.11 (2H,); 3.79 (s, 3H); 3.70 (s, 3H), 
2.97-2.91(t, 3H, J=6 3H); 2.67-2.64 (t, 2H J=6); 2.06 (s, 3H). 13C NMR δ 174.17, 
158.27,157.38, 142.10, 136.27,135.51, 133.56, 131.87,130.95,129.98, 129.38, 128.52, 
126.14, 121.19, 115.53, 111.35, 69.85, 56.12, 52.33, 36.71, 30.85, 16.45  
For 2.6 1HNMR (300MHz) (CDCl3) δ7.3-6.9 (m, 11H); 5.11 (2H,); 3.7 (s, 3H); 
2.98-2.93 (t, 2H, J=6); 2.72-2.67 (t, 2H J=6); 2.17 (s, 3H). 13C NMR δ 178.52, 
157.63,156.65, 139.38, 135.56, 134.79,132.48, 131.16 , 130.81, 130.25, 129.27, 129.05, 
128.66, 128.66, 127.98, 125.43, 120.48, 114.92, 110.62, 69.15, 55.42, 35.79, 29.79, 16.45 
 
 
Reaction scheme 3 was also performed using the same procedures as reaction 
scheme 1 (Figure 8). The 
only difference being 5-
bromo-2-methyl benzoic acid 
was used instead. The 
corresponding NMR 
readings are as follows. 3.2: 
1HNMR (300MHz) (CDCl3) 
δ 7. 49(s, 1H,); 7.29-7.26 (d, 
 
21 
 
 
 
1H, J=9); 7.01-6.98 (d, 1H, J = 9).  4.6 (s, 2H); 2.21 (s, 3H). 13C NMR δ 141.64, 134.44, 
131.40, 129.61, 127.27, 125.49, 119.08, 61.96, 17.39. The peak at 61 confirmed that the 
reduction had taken place. The crude NMR for 3.3 is as follows, 1HNMR (300MHz) 
(CDCl3) δ 7. 49 (s, 1H,); 7. 48- 7.0 (m, 2H,); 4.64 (s, 2H); 2.4 (s, 3H). 13C NMR δ 
137.56, 136.08, 131.76, 129.82, 128.97, 119.53, 43.90, 18.35. From the 13C NMR, the 
peak around 43 confirmed the formation of the chloride. Pure NMR for 3.4 was 1HNMR 
(300MHz) (CDCl3) δ7.6(s, 1H); 7.6-6.9 (m, 4H), 6.95 (m, 2H), 4.9 (s, 2H); 3.7 (s, 3H); 
2.30-2.8 (t, 2H, J=6); 2.7-2.6 (t, 2H J=6); 2.32 (s, 3H). 13C NMR δ 173.38, 157.16, 
137.23, 135.23, 133.24, 131.96, 131.03, 130.96, 119.62, 67.80, 51.62, 30.95, 18.43. 
 NMR for 3.5 1HNMR (300MHz) (CDCl3) δ 7.45 (s, 1H); 7.45-6.96 (m, 10H); 
5.09 (s, 2H,); 3.8 (s, 3H); 3.70 (s, 3H), 2.97-2.92 (t, 2H, J=6); 2.67-2.44 (t, 2H J=6); 2.20 
(s, 3H). 13C NMR δ 173.48, 157.55, 156.51, 136.32, 135.51, 134.49, 132.84, 130.81, 
130.40, 130.18, 129.95, 129.27, 129.27, 128.54, 120.83, 114.85, 111.19, 68.88, 55.52, 
51.00, 36.03, 30.16, 18.70. For 3.6:
 
1HNMR (300MHz) (CDCl3) δ7.35 (s, 1H); 7.35-6.95 
(m, 10H); 5.08 (2H,); 3.8 (s, 3H); 2.97-2.91(t, 2H, J=6); 2.71-2.43 (t, 2H J=6) ; 2.4 (s, 
3H). 13C NMR δ 178.71, 157.60, 156.49, 136.30, 135.50, 134.44, 132.48, 130.80, 130.39, 
130.17, 129.26, 129.26, 128.52, 120.83, 114.95 , 111.05, 68.87, 55.51, 35.84, 29.79, 
18.69.  
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CHAPTER III 
3. ASSAYS TO EVALUATE VDR ANTAGONISTS 
  
3.1. Luminescence and detection 
Luminescence is the emission of light due to the transition of electrons from 
molecular orbitals of higher energy to those of lower energy, usually the ground state or 
the lowest unoccupied molecular orbitals. When electrons return to a ground state from 
being in an excited state, they release energy in the form of light (Figure 12). 
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Figure 12: Schematic diagram depicting the generation of light from luminescent 
molecules in the excited state 
   
Luminescence is classified according to the excited state that gives rise to it and to the 
source of the energy that caused the excited state to be populated with electrons. The 
promotion of electrons to an excited state is called excitation. In many cases, this is 
brought about by absorption of visible or ultraviolet radiation. In such a case, if 
luminescence arises because electrons are relaxing from a singlet excited state to a singlet 
ground state, then it is called fluorescence. If the excitation is the result of energy 
released in a chemical reaction, the luminescence is called chemiluminescence. A subset 
of chemiluminescence occurring in the biosphere as a result of biological processes is 
called bioluminescence. 
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To detect the luminescent signal, the luminometer, illustrated in Figure 13, uses the single 
photon counting measurement technique, which is based on a photomultiplier tube 
(PMT).  
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Luminometer detection system. 
 
The luminescence system consists of the following parts: luminescence fiber 
bundle, filter wheel, and PMT detector. The luminescence fiber bundle guides the light 
from the sample, to the filter wheel, and finally to the detector. The filter wheel has six 
filter positions better isolate the analytical signal. The photon counting module (PCM) is 
designed to amplify and quantify the amount of light. Therefore, a photon of radiation 
25 
 
 
 
entering the tube strikes the cathode of the PCM, causing the emission of several 
electrons. These electrons are accelerated towards the first dynode. The electrons strike 
the first dynode, causing the emission of several electrons for each incident electron. 
These electrons are then accelerated towards the second dynode, to produce more 
electrons which are accelerated towards dynode three and so on. Eventually, the electrons 
are collected at the anode. Luminescence is read from the top of the well and collects as 
much light as possible, in order to maximize the luminescent signal. The signals from the 
detector are then digitalized with a computer.  
3.2 Fluorescence polarization and detection 
Fluorescence polarization measures the changes in the orientation of plane 
polarized light brought about by fluorophores that undergo rapid molecular motion 
during their fluorescence lifetime[29, 30]. (Figure 14) 
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Figure 14: Fluorescence Polarization Assay principle [31] 
The lifetime of fluorescence is the period of time between absorption of an 
excitation photon and the emission of a photon through fluorescence[30, 32]. 
Monochromatic light is passed through a polarization filter to generate polarized 
monochromatic light. The light absorbed and emitted by big fluorescent molecules 
remains mostly polarized and enters another parallel and perpendicular polarized 
emission filter detecting a high fluorescence polarization (FP) signal. In the contrary, a 
small fluorescent molecules depolarize light and a low FP signal is detected after a 
parallel and perpendicular emission filter. 
For the detection of FP we were using a multi-plate reader Tecan M1000. Here, 
light from the light source enters the monochromator through the entrance slit (Figure 
15).   
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Figure 15: Fluorescence detection 
 
The light beam is then collimated, and then strikes the dispersing element at an 
angle. The beam is split into its component wavelengths by the grating. Radiation of only 
a particular wavelength leaves the monochromator through the exit slit. The light then 
goes to the reading chamber and is reflected to the sample. Once the light interacts with 
the sample it is guided by the fiber bundle to the PMT detector. 
3.3. The VDR-Coregulator FP assay 
Fluorescence polarization (FP) was used to quantify the inhibition of the 
interaction between VDR-LBD and its coactivator protein SRC2-3 (Figure 16).[29] 
 
Figure 16: Cartoon of fluorescent polarization assay used to screen inhibitors 
 
The fluorescently labeled peptide SRC2-3 molecule free in solution is excited with 
monochromatic polarized light at a wavelength of 635 nm. Due to its small molecular 
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weight, the molecule tumbles rapidly in the solution causing the emission at 685 nm of 
depolarized light thus a low amount of polarized light can be detected after applying a 
parallel and perpendicular filter. When the MBP-VDR-LBD protein binds to the ligand 
LG190178, the ligand-receptor complex can recruit the fluorescently labeled peptide 
SRC2-3. Consequently, the molecular weight of the resulting complex is increased 
significantly, and therefore the complex tumbles more slowly. It causes more emitted 
light to remain polarized in the same plane as the excitation plane. Therefore a high 
polarization signal is detected after applying a parallel and perpendicular filter allowing 
the detection of a ligand-binding to a larger macromolecule. For this assay, VDR-LBD 
was expressed as a MBP analog in E. coli and purify by affinity chromatography.[33] 
The coregulator peptide SRC2-3 was used because it exhibited the highest affinity 
towards VDR.[33] The coregulator peptide SRC2-3 was labeled with a far red 
AlexaFluor 647 dye to reduce the background fluorescence due to compound 
aggregation. In order to enable binding between VDR and SRC2-3, a synthetic analog of 
vitamin D referred to as LG190178[34] was used, which was identified by Ligand 
Pharmaceuticals[35] . The structure is shown in (Figure-17).  
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Figure 17: LG190178: Synthetic Agonist for Vitamin D Receptor. 
All reagent were incubated in a volume of 0.02 ml in the presence of compound in a 
black 384-well plate and FP was read after 1 hour of incubation. The data was analyzed 
with GraphPrism.  
3.4 The VDR-mediated transcription assay 
The ability of VDR antagonists to inhibit VDR-mediated transcription were measured 
in commercially available embryonic renal cells (Hek 293T). Hek 293T cells contain, 
the simian vacuolating (SV) virus 40 T-antigen that allows for episomal replication of 
transfected plasmids containing the SV40 origin of replication. This allows for 
amplification of transfected plasmids and extended temporal expression of the desired 
gene products. This cell line is highly transfectable and grows, fairly easily, making it 
greatly valuable for these studies.  
Two vectors, VDR-CMV, a chimeric vector bearing VDR under control of a 
cytomegalovirus promoter, and a second vector, 24OH luciferase, containing luciferase 
under control of a the 24OH promoter, were transfected into the Hek 293T cells. The 
luciferase reporter vector allows the quantification of VDR-mediated gene transcription, 
because 24OH is a VDR target gene (Figure 18).  
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Figure 18: 24OH luciferase plasmid vector [36] 
The binding between VDR and the 24OH luciferase plasmid results in the 
expression of luciferase enzyme that catalyzes a bioluminescent reaction. The light 
emitted from the chemical reaction is directly proportional to the amount of expressed 
enzyme, and thus, the transcriptional activity of VDR. After 18 hours, the cells are lysed 
and the substrate of luciferase, luciferin, is introduced into the cellular extract along with 
Mg and excess ATP (Figure 19).  
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Figure 19: Enzymatic reaction of luciferase. 
The luciferase enzyme acts on luciferin in the presence of magnesium cations and 
oxygen. The oxidation of luciferin releases energy in the form of luminescence or 
light.[37] The luminescence from this chemical reaction can be read and quantified by a 
luminescence reader. The amount of light detected from the cell lysate correlates directly 
with the inhibition of binding between VDR and coactivators, an interaction which is 
essential for VDR-mediated transcription.  
3.5 Toxicity assay 
 
The cytotoxicity of VDR antagonists was determined by luminescence using Cell 
Titer-Glo reagent (Promega). The cytotoxicity assay allows for the determination of the 
number of viable cells in culture based on quantification of the ATP present, an indicator 
of metabolically active cells. The toxicity assay procedure involves adding the single 
reagent Cell Titer-Glo Reagent directly to cell culture. The Cell Titer-Glo reagent 
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contains a surfactant, which causes cell lysis for ATP liberation. The APT is converted by 
an enzymatic reaction generating a luminescent signal that is proportional to the amount 
of ATP liberated. CellTiter-Glo provides the purified luciferin and luciferase necessary to 
measure ATP using a bioluminescent reaction.  
3.6 Experimental procedures 
3.6.1. Protocol to determine the interaction between VDR and coregulator SRC2-3 
This assay was conducted in 384-well black polystyrene plates (Corning) using a 
buffer [25 mM PIPES (pH 6.75) 50 mM NaCl, 0.01% NP-40, 2% DMSO, VDR-LBD 
protein (0.1 µM), LG190178 (0.75 µM), and Alexa Fluor 647-labeled SRC2-3.  Small 
molecule transfer into a 20 µL assay solution was accomplished using a stainless steel pin 
tool (V&P Scientific), delivering 100 nL of the serially diluted compound solution (1:3 
dilution starting at a 10mM concentration).  Fluorescence polarization was detected after 
initial mixing at excitation and emission wavelengths of 650 and 665 nm (Alexa 
Fluor647). Three independent experiments were conducted in quadruplicate, and data 
were analyzed using nonlinear regression with a variable slope using GraphPadPrism 
software.  
3.6.2. Protocol to determine the VDR-mediated inhibition of transcription  
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The Hek293T cells were collected from a liquid nitrogen tank and 1ml was 
pipetted into a 75 cm2   cell culture flask containing 14ml of media, DMEM/High 
Glucose. The media contains non-essential amino acids, 2 mM L-glutamine, 1 mM 
sodium pyruvate, and 1500mg/L sodium bicarbonate. The flask is then placed in an 
incubator 37°C and 5 percent carbon dioxide until they reached 80 to 90 percent 
confluency.  
 
Matrigel: The purpose of matrigel for this assay is to coat the bottom of the flask and the 
384 well plates so that the cells can attach to the bottom. The solution is prepared by 
taking 100mL of phenol red-free DMEM and 250 µL of Matrigel concentrate. Matrigel is 
the name for a gelatinous protein secreted by mouse sarcoma. 3 ml of Matrigel solution 
are added to the flask and incubate for 5 minutes. The solution is replace with growth 
media followed by the addition of cells.  
 
Trypsin: Trypsin-EDTA is the most commonly used method for passaging adherent 
cells.  Trypsin treatment disrupts the cell monolayer and a proteolytically cleave the 
bonds between cells and cells and flask. Often gentle pipetting after trypsin treatment 
dissociates all cell clumps into single cells. 
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Lipofectamine: Allows the transfer of DNA into eukaryotic cells with minimum damage 
to the cells or plasmid. Since DNA is a charged molecule moving it past the hydrophobic 
cell membrane can be a challenge. Lipofectamine is used in lipid-based methods of 
transfection. The cationic head group associates with the anionic phosphates groups on 
the nucleic acids. A lipid-DNA complex can pass through the cell membrane, either by 
endocytosis or by fusion with the plasma membrane.  
 
Plus Reagent: The Plus Reagent is used for pre-complexing DNA that enhances cationic 
lipid-mediated transfection of DNA into the cells. 
Passaging and splitting cells: Cells could be split as early as when they are at 30% 
confluency. They are passaged first by aspirating the old media and then rinsing the cells 
with PBS buffer, which washes away dead cells floating on the flask. To detach the cells 
that were attached to the flask, by using 0.05 percent trypsin and incubating the flask for 
5 minutes at 37°C and 5 percent carbon dioxide incubator. After 5 minutes, the cell 
suspension was mixed by pipette in order to achieve a single cell suspension. Cells are 
split into 3 new flasks. 3 ml of Matrigel is first pipetted into the new flasks and incubated 
at 37°C degree for 5 minutes. The matrigel is aspirated out and 14 ml of the growth 
media, DMEM/High Glucose (Hyclone, catalog no. SH3028401), nonessential amino 
acids, sodium pyruvate (1mM), HEPES (10 mM), penicillin and streptomycin, and 2% 
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charcoal-treated FBS (Invitrogen, catalog no. 12676-011);1ml of the cells in trypsin is 
added to each flask. 
VDR Transfection: When the cells reach about 80% confluency, 2 mL of untreated 
DMEM containing 1.2 µL of VDR-CMV (649.7 nm/µL) thus 0.78 µg; 5.1 µL of 24OH-
luciferase (514.2 ng/ µL) thus 15.6 µg, and 25 µL of Plus Reagent were added and 
incubated for 5 minutes at room temperature. After the 5 minutes, 75 µL Lipofectamine 
was added and the mixture was incubated for 30 minutes on the shaker at room 
temperature. The mixture was then added to the flask containing the cells and incubated 
overnight. After 18h, 3mL of 0.05% trypsin (Hyclone, catalog no. SH3023601) was 
added and the mixture was incubated so that the cells were completely detached from the 
bottom of the flask. After converting the mixture into a single cell solution by pipetting 
up and down a few times. The trypsinized cells were added to 12 mL of DMEM/High 
Glucose (Hyclone, catalog no. SH3028401), nonessential amino acids, sodium pyruvate 
(1 mM), HEPES (10 mM), penicillin and streptomycin, and 2% charcoal-treated FBS 
(Invitrogen, catalog no. 12676-011), and spun down for 2 min at 1000 rpm. The media is 
removed leaving behind the pellets at the bottom. The cell were re-suspended in the same 
medium and diluted to 16 ml. 20 µL of Matrigel was added into rows of white clear 
bottom 384-well plates and incubate at 37°C for 5 minutes. The Matrigel solution is 
removed from 384 well plate and 20 µL of the cell solution was added to specific rows on 
the plate. The plates are, centrifuged and incubated for five hours. After the 5 hours, 
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compounds and control plates were added to cells using the Pintool (2x transfer of 
compounds and 1x transfer of control plate) and incubated for 18 hours. Controls are, 
DMSO (negative) and cell with were not treated with agonist calcitriol. After the 18 
hours, the Bright Glo luciferase reagent was warmed up and 20 ul of it was added to each 
well containing the cells. After a quick shake on a shaker and centrifugation at 1000 rpm 
for one minute the plate was incubated for 20 minutes. Luminescence was measured 
using Tecan M1000 and % inhibition was determined using the controls.  
 
3.6.3. Protocol to determine the PPAR𝜹-mediated inhibition of transcription 
The assay for the PPAR𝛿 was performed the same way as the VDR-mediated 
transcription assay except, 1500ng of PPARδ GAL4 (814.4 ng/ µL) and 16,000ng 
GAL4REluc (543.1 ng/µL) were added. The same amount of Plus Reagent and 
Lipofectamine were used. On the control plate, GW7647 (30 nM), a PPARδ agonist,  was 
used as a positive control and DMSO was used as a negative control.[38] 
Preparation of drug plates: The compound plate was prepared by first dissolving the 
compound in DMSO to get 10mM solution. 90 µL of 10 mM solution of the small 
molecule was put in the first well of a 96-well plate and a 1:3 dilution was made in 
DMSO filling rows 1 to 10. Using the multi-channel pipette, 20 µL of serial diluted small 
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molecule were pipetted to 384 well opaque drug plate filling rows 1 to 20. The 
experiment was done in quadruplets A1, A2, B1, B2; all have the same concentration. A 
second 384-well polystyrene plate, the control plate, had calcitriol on wells 1-20 and 
positive and negative controls. DMSO was the negative control for the antagonist assay. 
For the agonist assay, the control plate had DMSO as a positive control and calcitriol as a 
negative control.  
3.6.4 Protocol to determine the viability of cells  
Hek 293T cells were also used for this assay and were cultured, plated, and 
drugged in the same manner as described in the transcription assay chapter. Cells were 
plated the same way in a 384 well plate. After 5 hours the compound and control were 
added to the cells and incubated at 37 °C for 18 hours. To perform the luciferase assay, 
20 µL of the Cell Titer-Glo reagent was added to each well of the 384-well plate that 
contained the cells using a multi-channel pipette. The plate was centrifuged for 2 minutes 
at 1,000 rpm and allowed to sit for 20 minutes. The Tecan Infinite M-1000 multi-label 
reader was used to measure the amount of luminescence generated from each well.  
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CHAPTER IV 
4. SUMMARY OF RESULTS 
 
4.1 BF050813G  
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Figure 20: Summary of BF050813G; A) FP; B) VDR-mediated transcription (antagonist 
mode); C) Toxicity; D) PPARδ-mediated transcription (agonist mode) 
 
The FP assay, BF050813G did not show a significant change in signal and hence 
no IC50 values were calculated (Figure 20A). However, VDR-mediated transcription was 
inhibited (significant decrease in the luminescence) at higher concentrations with an IC50 
value of 43 µM (Figure 20B). In addition, there was also no signal change for the PPARδ 
activity (Figure 20D), and toxicity assays (Figure 20C).  
4.2 BF040813F  
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Figure 21: Summary of BF040813F; A) FP; B) VDR-mediated transcription (antagonist 
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode) 
 
Compound BF040813F showed activity towards VDR in both, the fluorescence 
polarization assay (Figure 21A) and VDR-mediated transcription assay (Figure 21B), 
with IC50 ~4.37 µM and IC50 = 13.96 ± 3.54 µM, respectively. BF040813F is not toxic 
and is not active as PPARδ agonist (Figure 21C & D).  
 
 
4.3 BF060813H 
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Figure 22: Summary of BF060813H; A) FP; B) VDR-mediated transcription (antagonist 
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode) 
 
BF060813H is active in fluorescence polarization assay with an IC50 of ~5.6 µM 
(Figure 22A). The activity in cells for the VDR-mediated transcription assay is IC50 = 
32.57 ±7.55 µM (Figure 22B). BF060813H is nontoxic and is not able to activate 
PPARδ-mediate transcription (Figure 22C&D). 
4.4 BF090713B 
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Figure 23: Summary of BF090713B; A) FP; B) VDR-mediated transcription (antagonist 
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode) 
 
Although activity is observed for BF090713B in the VDR FP assay a non-linear 
regression was not possible due to missing data points at higher concentrations (Figure 
23A). The IC50 value for the VDR-mediated transcription study was 38.31 ± 19.39 µM 
(Figure 23B). BF090713B is nontoxic (Figure 23C) and has no agonistic activity with 
PPARδ (Figure 23D). 
 
4.5 BF090613C 
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Figure 24: Summary of BF090613C; A) FP; B) VDR-mediated transcription (antagonist 
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode) 
 
The IC50 values could be calculated accurately for compounds BF090613C in the 
transcription assay, which was 20.87 ± 10.13 µM (Figure 24B). However, as mentioned 
above, the accurate calculation of the IC50 values was not possible for the fluorescence 
polarization assay due to insufficient data (Figure 24A). Compound BF090613C also 
showed toxicity between 30 µM and 100 µM (Figure 24C). Compared to the previously 
described compounds, this compound has shown the highest toxicity. There was no 
transcriptional activation of the PPARδ (Figure 24D).  
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4.6 BF090813A 
 
 
Figure 25: Summary of BF090613C; A) FP; B) VDR-mediated transcription (antagonist 
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode) 
 
Compound BF090813A is a VDR antagonist indicated by both the fluorescence 
polarization (Figure 25A) and VDR-mediated transcription assay (Figure 25B) with an 
IC50 values of 19.63 ± 6.08 µM and 32.57± 7.55 µM respectively. BF090813A did not 
show toxicity at the concentrations tested (Figure 25C) but showed a partial agonist 
behavior with PPARδ.  8% activity was observed at concentration of 100 µM 
BF090813A (Figure 25A).    
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4.7 BF090712D  
 
 
Figure 26: Summary of BF090712D; A) FP; B) VDR-mediated transcription (antagonist 
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode) 
 
Compound BF090712D shows activity at higher concentrations in the 
fluorescence polarization assay but an IC50 value calculation was not possible due to 
insufficient data (Figure 26A). The transcription assay (Figure 26B), however, shows 
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the compound is an antagonist with an IC50 value of 6.54 ± 1.7 µM.  This compound is 
also nontoxic as most of the other analogues (Figure 26C). BF090712D is able to 
activate transcription mediated by PPARδ. There is 32% activity at 0.5 µM in comparison 
with PPARδ agonist GW7647 (Figure 26D).   
4.8 BF090713B1 
 
 
Figure 27: Summary of BF090613B1; A) FP; B) VDR-mediated transcription (antagonist 
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode) 
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Compound BF090713B1 is a VDR antagonist as determined by the FP and transcription 
assays. IC50 values determined for both assays are very similar, 22.0 ± 9.99 µM and 21.27 
± 3.19 µM for the FP (Figure 27A) and transcription assays (Figure 27B), respectively. 
This compound was also determined to be nontoxic at the concentrations tested (Figure 
27C). There was also no activity with PPARδ (Figure 27D). 
 
4.9 BF090613C1 
 
 
 
 
 
 
 
 
Figure 28: Summary of BF090613C1; A) FP; B) VDR-mediated transcription (antagonist 
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode) 
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Compound BF090613C1 is active in the VDR FP assay and the VDR mediated 
transcription assay. The IC50 value in the FP assay (Figure 28A) is 7.5 ± 3.41 µM and the 
IC values of the transcription assay (Figure 28B) is 34.50 µM. BF090613C is not toxic 
(Figure 28C) and is not able to activate PPARδ-mediated transcription (Figure 28D). 
 
4.10 BF090813A1 
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Figure 29: Summary of BF090613C1; A) FP; B) VDR-mediated transcription (antagonist 
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode) 
 
Compound BF090813A1 is active in the FP assay (IC50 = 9.4 ± 3.44 µM)  (Figure 
29A) and in the transcription assay (Figure 29B) (IC50 = 21.06 ± 7.2 µM). This VDR 
antagonist is nontoxic (Figure 29C). In terms of agonistic activity with PPARδ, there is 
8% activity at 40 µM (Figure 29D).   
 
4.11 F090812E 
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Figure 30: Summary of BF090613C1; A) FP; B) VDR-mediated transcription (antagonist 
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode) 
 
Compound BF090812E is also an antagonist of VDR as determined by the FP and 
Transcription assays. IC50 values determined for both assays are very similar, 12.2 ± 6.8 
µM (Figure 30A) and 14.4 ± 10.2 µM (Figure 30B) for the FP and transcription assays, 
respectively. This compound was also determined to be nontoxic at the concentrations 
tested (Figure 30C). In addition, minor PPARδ activity (Figure 30D) was detected with 
an activation of 19% in comparison with agonist GW7647 at concentration of 10 µM. 
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CHAPTER V 
5. DISCUSSION AND CONCLUSIONS 
 
In total, 11 compounds were investigated with respect to their ability to bind VDR 
and inhibit the recruitment of coagulators. The design of the compounds was based on the 
scaffold of GW0742, a potent PPARδ agonist, substituting the thiazole moiety with a 
phenyl ring. The compounds also exhibit a different connectivity of the two moieties of 
the GW0742 scaffold, which was realized with the thiazole-phenyl switch. The goal of 
this research was, in respect to GW0742, to improve the affinity towards VDR and 
reduce the agonistic effects towards PPARδ.    
The activity of compounds was measured with a biochemical FP assay that 
determines the inhibition of VDR binding to coregulator peptide SRC2-3. All of the 
scaffolds demonstrated the ability to inhibit the VDR-SRC2-3 interaction. The 
compounds were also tested towards their ability to bind unliganded VDR and enable the 
recruitment of SRC2-3 in an agonist mode. None of the compound were VDR agonists 
(results not shown). On the other hand, they all show some level of inhibition in the 
antagonist mode. The most active inhibitor was compound BF060813H, a precursor for 
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the final compound BF090813A1, which is an active VDR antagonist as well. The other 
precursors BF050813G and BF060813H had a much lower activity. The final carboxylic 
acid compounds BF090813A1, BF090713b1, and BF090613C1 bearing a methoxy 
substituent were significantly more active than the corresponding methyl ester 
compounds BF090713B, BF090613C, and BF090813A.   
In addition, all compound were investigated using a VDR-mediate transcription 
assay. In cells, the inhibition of VDR-coactivator interactions will result in the inhibition 
of transcription; in this case the transcription of the luciferase enzyme. Among the 
precursor compounds BF060813H, which also exhibited high activity in the FP assay was 
able to inhibit VDR-mediated transcription in cells with an IC50 value of 4.3 µM. The 
other precursors BF050813G and BF060813H were less active. The methyl ester 
compounds BF090713B, BF090613C, and BF090813A, similar to the results of the FP 
assay, were less active than the final carboxylic acid compounds. The methyl ester 
BF090712D, however, exhibited a high activity in the cell-based assay but weak activity 
in the FP assay. In addition, we observed a decreasing cell viability at higher 
concentration of BF090712D, which in addition to inhibition of transcription will lower 
the luminescence signal due to the decreased amount of viable cells. All final products 
BF090813A1, BF090713b1, BF090613C1, and BF090812E showed a good activity in 
the transcription assay without any signs of toxicity. Compound BF090812E was the 
most active among these final compound with an IC50 of 14.4 µM. 
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Because these compound were structurally derived from GW0742, a PPARδ 
agonist, the activity of all compounds towards PPARδ was determined. Only three 
compounds showed a partial activity towards PPARδ, which include BF090813A, 
BF090712D, and BF090812E. The methyl ester BF090712D was the most potent PPARδ 
agonist with an IC50 value of around 1 µM and an activation of almost 50% in respect to 
GW7647. The methyl ester BF090813A was significantly less active than BF090712D 
with an 8% activity in respect to GW7647 at 100 µM. Finally, BF090812E, bearing a 
hydroxymethyl group instead of a methoxy group is the only final compound that 
activated PPARδ transcription at a level of 19% at 100 µM. 
Overall a series of new VDR antagonists were generated and evaluated using 
several biochemical and cell-based assays. The introduction of a 2-methoxy group 
minimized the activity of the final compounds towards PPARδ, which was confirmed by 
the elevated PPARδ activity of 4-hydroxy substituted compounds BF0908122E. The 
methyl ester compounds were generally less active in the FP assay than in the cell-based 
assay, which might have to do with the poor solubility but good permeability of these 
compounds. BF090813A1 was the most active compounds towards VDR without 
residual activity towards PPARδ. Surprisingly, among the precursor compounds, 
BF040813F exhibited a similar VDR activity and selectivity than BF090813A1. The 
synthesis of BF040813F, in comparison with BF09081A1, is shorter and the molecule 
can be produced in a higher yield. A possible continuation of this program might use 
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BF040813F as parent compound and investigate the ability of compounds similar to 
BF040813F to inhibit VDR-mediated transcription.  
 
 
 
 
 
CHAPTER VI 
1. SUMMARY OF DATA 
 
Table 1: Summary of the compounds tested, with respect to their ability to inhibit VDR-
mediated transcription, VDR-SRC2-3 interaction (FP assay), as well as their 
cytotoxicity. All results are given in micromolar concentrations. 
Structure and ID 
VDR-SRC2-3 
interaction 
IC50 Values 
(µM) 
Inhibition of 
VDR-Mediated 
Transcription 
IC50 Values 
(µM) 
Transcription 
Assay: PPARd 
Agonist (EC50) 
µM 
Toxicity (LD50) 
µM 
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Low activity 
 
 
43.19 
 
 
No Activity 
 
Non-Toxic 
 
 
 
4.37 
 
 
13.96 
 
 
No Activity 
 
Non-Toxic 
  
 
 
5.6 
 
 
32.57 
 
 
No Activity 
 
Non-Toxic 
  
 
Low activity 
 
 
38.31 
 
 
No Activity 
 
Non-Toxic 
 
 
 
Low activity 
 
 
20.87 
 
 
No Activity 
 
Toxic 
at 100 uM 
 
 
 
19.63 
 
 
32.57 
 
 
 8% activity 
 
Non-Toxic 
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Low activity 
 
 
6.54 
 
 
32 % activity 
 
Non-Toxic 
 
 
 
 9.40 
 
 
 
21.06 
 
 
No Activity 
 
Non-Toxic 
  
 
22.00 
 
 
21.27 
 
 
No Activity 
 
Non-Toxic 
 
 
 
7.5 
 
 
34.5 
 
 
No Activity 
 
Non-Toxic 
 
 
 
12.20 
 
 
14.45 
 
 
19% 
 
Non-Toxic 
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